Camelpox virus (CMLV) is the closest known orthopoxvirus genetically related to variola virus. So far, CMLV was restricted to camelids but, recently, three human cases of camelpox have been described in India, highlighting the need to pursue research on its pathogenesis, which has been hampered by the lack of small animal models. Here, we confirm that NMRI immunocompetent mice are resistant to intranasal (i.n.) CMLV infection. However, we demonstrate that CMLV induced a severe disease following i.n. challenge of athymic nude mice, which was accompanied with a failure in gaining weight, leading to euthanasia of the animals. On the other hand, intracutaneous (i.c.) infection resulted in disease development without impacting the body weight evolution. CMLV replication in tissues and body fluids was confirmed in the two models. We further analyzed innate immune and B cell responses induced in the spleen and draining lymph nodes after exposure to CMLV. In both models, strong increases in CD11b+F4/80+ macrophages were seen in the spleen, while neutrophils, NK and B cell responses varied between the routes of infection. In the lymph nodes, the magnitude of CD11c+CD8α+ lymphoid and CD11c+CD11b+ myeloid dendritic cell responses increased in i.n. challenged animals. Analysis of cytokine profiles revealed significant increases of interleukin (IL)-6 and IL-18 in the sera of infected animals, while those of other cytokines were similar to uninfected controls. The efficacy of two antivirals (cidofovir or HPMPC, and its 2, 6-diaminopurine analog) was evaluated in both models. HPMPC was the most effective molecule affording 100% protection from morbidity. It appeared that both treatments did not affect immune cell responses or cytokine expression. In conclusion, we demonstrated that immunodeficient mice are permissive for CMLV propagation. These results provide a basis for studying the pathogenesis of CMLV, as well as for evaluating potential antiviral therapies in an immunodeficiency context.
References
[1]
Afonso CL, Tulman ER, Lu Z, Zsak L, Sandybaev NT, et al. (2002) The genome of camelpox virus. Virology 295: 1–9.
[2]
Gubser C, Smith GL (2002) The sequence of camelpox virus shows it is most closely related to variola virus, the cause of smallpox. J Gen Virol 83: 855–872.
[3]
Wernery U, Zachariah R (1999) Experimental camelpox infection in vaccinated and unvaccinated dromedaries. Zentralbl Veterinarmed B 46: 131–135.
[4]
Al Zi'abi O, Nishikawa H, Meyer H (2007) The first outbreak of camelpox in Syria. J Vet Med Sci 69: 541–543.
[5]
Wernery U, Kaaden OR (2002) Infectious diseases in camelids. pp. 176–187.
[6]
Davies FG, Mungai JN, Shaw T (1975) Characteristics of a Kenyan camelpox virus. J Hyg (Lond) 75: 381–385.
[7]
Jezek Z, Kriz B, Rothbauer V (1983) Camelpox and its risk to the human population. J Hyg Epidemiol Microbiol Immunol 27: 29–42.
[8]
Kriz B (1982) A study of camelpox in Somalia. J Comp Pathol 92: 1–8.
[9]
Bera BC, Shanmugasundaram K, Barua S, Venkatesan G, Virmani N, et al. (2011) Zoonotic cases of camelpox infection in India. Vet Microbiol In press.
[10]
von Bomhard W, Mauldin EA, Breuer W, Pfleghaar S, Nitsche A (2010) Localized cowpox infection in a 5-month-old Rottweiler. Vet Dermatol 22: 111–114.
[11]
Ninove L, Domart Y, Vervel C, Voinot C, Salez N, et al. (2009) Cowpox virus transmission from pet rats to humans, France. Emerg Infect Dis 15: 781–784.
[12]
Kurth A, Straube M, Kuczka A, Dunsche AJ, Meyer H, et al. (2009) Cowpox virus outbreak in banded mongooses (Mungos mungo) and jaguarundis (Herpailurus yagouaroundi) with a time-delayed infection to humans. PLoS One 4: e6883.
[13]
Campe H, Zimmermann P, Glos K, Bayer M, Bergemann H, et al. (2009) Cowpox virus transmission from pet rats to humans, Germany. Emerg Infect Dis 15: 777–780.
[14]
Glatz M, Richter S, Ginter-Hanselmayer G, Aberer W, Mullegger RR (2010) Human cowpox in a veterinary student. Lancet Infect Dis 10: 288.
[15]
Bhanuprakash V, Venkatesan G, Balamurugan V, Hosamani M, Yogisharadhya R, et al. (2009) Zoonotic Infections of Buffalopox in India. Zoonoses Public Health 57(7-8): e149–155.
[16]
Abrahao JS, Silva-Fernandes AT, Lima LS, Campos RK, Guedes MI, et al. (2010) Vaccinia virus infection in monkeys, Brazilian Amazon. Emerg Infect Dis 16: 976–979.
[17]
Silva DC, Moreira-Silva EA, Gomes JA, Fonseca FG, Correa-Oliveira R (2010) Clinical signs, diagnosis, and case reports of Vaccinia virus infections. Braz J Infect Dis 14: 129–134.
[18]
Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, et al. (2010) Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A 107: 16262–16267.
[19]
Abu Elzein EM, Gameel AA, Ramadan RO, Housawi FM (1999) An eruptive moderate form of camelpox infection in dromedary camels (Camelus dromedarius) in Saudi Arabia. Rev Sci Tech 18: 749–752.
[20]
Kinne J, Cooper JE, Wernery U (1998) Pathological studies on camelpox lesions of the respiratory system in the United Arab Emirates (UAE). J Comp Pathol 118: 257–266.
[21]
Otterbein CK, Meyer H, Renner-Muller IC, Munz E (1996) In vivo and in vitro characterization of two camelpoxvirus isolates with decreased virulence. Rev Elev Med Vet Pays Trop 49: 114–120.
[22]
Bhanuprakash V, Balamurugan V, Hosamani M, Venkatesan G, Chauhan B, et al. (2010) Isolation and characterization of Indian isolates of camel pox virus. Trop Anim Health Prod 42: 1271–1275.
[23]
Hafez SM, al Sukayran A, dela CD, Mazloum KS, al Bokmy AM, et al. (1992) Development of a live cell culture camelpox vaccine. Vaccine 10: 533–539.
[24]
Pfeffer M, Meyer H, Wernery U, Kaaden OR (1996) Comparison of camelpox viruses isolated in Dubai. Vet Microbiol 49: 135–146.
[25]
Duraffour S, Snoeck R, de Vos R, van Den Oord JJ, Crance JM, et al. (2007) Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir Ther 12: 1205–1216.
[26]
Duraffour S, Vigne S, Vermeire K, Garcel A, Vanstreels E, et al. (2008) Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently. Antivir Ther 13: 977–990.
[27]
Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, et al. (2005) An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 79: 13139–13149.
[28]
Duraffour S, Snoeck R, Krecmerova M, Van den OJ, de Vos R, et al. (2007) Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models. Antimicrob Agents Chemother 51: 4410–4419.
[29]
Duraffour S, Andrei G, Snoeck R (2010) Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection. IDrugs 13: 181–191.
[30]
Hostetler KY (2009) Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 82: A84–A98.
[31]
Centers for Disease Control and Prevention (CDC) (2007) Household transmission of vaccinia virus from contact with a military smallpox vaccinee--Illinois and Indiana, 2007. MMWR Morb Mortal Wkly Rep 56: 478–481.
[32]
Centers for Disease Control and Prevention (CDC) (2009) Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb Mortal Wkly Rep 58: 532–536.
[33]
Centers for Disease Control and Prevention (CDC) (2009) Human vaccinia infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 58: 1204–1207.
[34]
Bristol N (2007) Adverse event related to smallpox vaccination. Disaster Med Public Health Prep 1: 11–12.
[35]
Kaiser J (2007) Smallpox vaccine. A tame virus runs amok. Science 316: 1418–1419.
[36]
Marris E (2007) Dramatic rescue relieves rare case of smallpox infection. Nat Med 13: 517.
[37]
Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, et al. (2008) Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 46: 1555–1561.
[38]
Baxby D (1972) Smallpox-like viruses from camels in Iran. Lancet 2: 1063–1065.
[39]
Falluji MM, Tantawi HH, Shony MO (1979) Isolation, identification and characterization of camelpox virus in Iraq. J Hyg (Lond) 83: 267–272.
[40]
Ramyar H, Hessami M (1972) Isolation, cultivation and characterization of camel pox virus. Zentralbl Veterinarmed B 19: 182–189.
[41]
Sehgal CL, Ray SN (1980) Studies on camelpox virus. J Commun Dis 12: 177–182.
[42]
Tantawi HH, El Dahaby H, Fahmy LS (1978) Comparative studies on poxvirus strains isolated from camels. Acta Virol 22: 451–457.
[43]
Tscharke DC, Reading PC, Smith GL (2002) Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 83: 1977–1986.
[44]
Osorio JE, Iams KP, Meteyer CU, Rocke TE (2009) Comparison of monkeypox viruses pathogenesis in mice by in vivo imaging. PLoS One 4: e6592.
[45]
Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, et al. (2010) A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J Virol 84: 3909–3920.
[46]
Americo JL, Moss B, Earl PL (2010) Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models. J Virol 84: 8172–8180.
[47]
Damon I (2007) Poxviruses. In: Knipe DM, Howley PM, editors. Fields Virology. Lippincot Williams & Wilkins. pp. 2947–2975.
[48]
Chapman JL, Nichols DK, Martinez MJ, Raymond JW (2010) Animal models of orthopoxvirus infection. Vet Pathol 47: 852–870.
[49]
Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, et al. (1997) Cytokines and immunity to viral infections. Immunol Rev 159: 119–135.
[50]
Smee DF, Gowen BB, Wandersee MK, Wong MH, Skirpstunas RT, et al. (2008) Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment. Int J Antimicrob Agents 31: 352–359.
[51]
Liu G, Zhai QZ, Schaffner DJ, Wu AG, Yohannes A, et al. (2004) Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma. Fems Immunology and Medical Microbiology 40: 201–206.
[52]
Quenelle DC, Collins DJ, Kern ER (2004) Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res 63: 33–40.
[53]
Smee DF, Bailey KW, Wong MH, Wandersee MK, Sidwell RW (2004) Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. Journal of Infectious Diseases 190: 1132–1139.
[54]
Grosenbach DW, Berhanu A, King DS, Mosier S, Jones KF, et al. (2010) Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Natl Acad Sci U S A 107: 838–843.
[55]
Neyts J, Leyssen P, Verbeken E, De Clercq E (2004) Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob Agents Chemother 48: 2267–2273.
[56]
Thin G (1882) The Histology of Molluscum Contagiosum. J Anat Physiol 16: 202–207.
Schoepp RJ, Morin MD, Martinez MJ, Kulesh DA, Hensley L, et al. (2004) Detection and identification of Variola virus in fixed human tissue after prolonged archival storage. Lab Invest 84: 41–48.
[59]
Karupiah G, Buller RM, Van Rooijen N, Duarte CJ, Chen J (1996) Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J Virol 70: 8301–8309.
[60]
Chaudhri G, Panchanathan V, Buller RM, van den Eertwegh AJ, Claassen E, et al. (2004) Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci U S A 101: 9057–9062.
Reading PC, Smith GL (2003) A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection. J Gen Virol 84: 1973–1983.
[63]
O'Gorman WE, Sampath P, Simonds EF, Sikorski R, O'Malley M, et al. (2010) Alternate mechanisms of initial pattern recognition drive differential immune responses to related poxviruses. Cell Host Microbe 8: 174–185.
[64]
Abadie V, Bonduelle O, Duffy D, Parizot C, Verrier B, et al. (2009) Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice. PLoS One 4: e8159.
[65]
Tscharke DC, Woo WP, Sakala IG, Sidney J, Sette A, et al. (2006) Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 80: 6318–6323.
[66]
Knorr CW, Allen SD, Torres AR, Smee DF (2006) Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection. Antiviral Res 72: 125–133.
[67]
Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12: 53–72.
[68]
Reading PC, Smith GL (2003) Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 77: 9960–9968.
[69]
Alcami A, Smith GL (1995) Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 69: 4633–4639.
[70]
Najarro P, Traktman P, Lewis JA (2001) Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol 75: 3185–3196.
[71]
Smee DF (2008) Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother 19: 115–124.
[72]
Gammon DB, Snoeck R, Fiten P, Krecmerova M, Holy A, et al. (2008) Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J Virol 82: 12520–12534.
[73]
Gubser C, Bergamaschi D, Hollinshead M, Lu X, van Kuppeveld FJ, et al. (2007) A new inhibitor of apoptosis from vaccinia virus and eukaryotes. PLoS Pathog 3: e17.
[74]
Gubser C, Goodbody R, Ecker A, Brady G, O'Neill LA, et al. (2007) Camelpox virus encodes a schlafen-like protein that affects orthopoxvirus virulence. J Gen Virol 88: 1667–1676.
